These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28323937)

  • 1. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
    Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of lymph node and distant metastases from papillary and poorly differentiated thyroid carcinomas.
    Máximo V; Melo M; Sobrinho-Simões M; Soares P; Da Cruz Paula A
    Endocrine; 2024 Nov; 86(2):505-509. PubMed ID: 39030377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.
    Fakhruddin N; Jabbour M; Novy M; Tamim H; Bahmad H; Farhat F; Zaatari G; Aridi T; Kriegshauser G; Oberkanins C; Mahfouz R
    Sci Rep; 2017 Jul; 7(1):4666. PubMed ID: 28680105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of
    Rusinek D; Pfeifer A; Krajewska J; Oczko-Wojciechowska M; Handkiewicz-Junak D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Cyplinska R; Zembala-Nozynska E; Chekan M; Chmielik E; Kropinska A; Lamch R; Jurecka-Lubieniecka B; Jarzab B; Czarniecka A
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30200646
    [No Abstract]   [Full Text] [Related]  

  • 7. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
    Cañadas-Garre M; Becerra-Massare P; Moreno Casares A; Calleja-Hernández MÁ; Llamas-Elvira JM
    Head Neck; 2016 Dec; 38(12):1772-1779. PubMed ID: 27299298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
    Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
    J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
    Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
    Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
    Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
    Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
    Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
    Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.
    Argyropoulou M; Veskoukis AS; Karanatsiou PM; Manolakelli A; Kostoglou-Athanassiou I; Vilaras G; Karameris A; Liadaki K
    Pathol Oncol Res; 2020 Jan; 26(1):347-354. PubMed ID: 30361901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic-prone telomerase reverse transcriptase (TERT) promoter and v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutated tall cell variant of papillary thyroid carcinoma arising in ectopic thyroid tissue: A case report.
    Stenman A; Koman A; Ihre-Lundgren C; Juhlin CC
    Medicine (Baltimore); 2021 Jan; 100(2):e24237. PubMed ID: 33466206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent BRAF
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.
    Censi S; Barollo S; Grespan E; Watutantrige-Fernando S; Manso J; Iacobone M; Casal Ide E; Galuppini F; Fassina A; Bertazza L; Vianello F; Pennelli G; Mian C
    Eur J Endocrinol; 2019 Jul; 181(1):1-11. PubMed ID: 31042674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Stratification Using a Novel Genetic Classifier Including
    Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
    Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
    [No Abstract]   [Full Text] [Related]  

  • 18. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
    Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
    Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F
    Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
    Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
    Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.